Monitoring the KMT2A gene post‐chemotherapy independently predicts the relapse and survival risk after allogeneic haematopoietic stem cell transplantation

• Published in: British journal of haematology Vol. 206; no. 5; pp. 1418 - 1429
• Main Authors: Liu, Jing, Zhao, Xiao‐Su, Chang, Ying‐Jun, Qin, Ya‐Zhen, Jiang, Qian, Jiang, Hao, Zhang, Xiao‐Hui, Xu, Lan‐Ping, Wang, Yu, Lv, Meng, Liu, Kai‐Yan, Huang, Xiao‐Jun, Zhao, Xiang‐Yu
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.05.2025
• Subjects: acute myeloid leukaemia; Acute myeloid leukemia; Adolescent; Adult; Aged; allogeneic haematopoietic stem cell transplantation; Allografts; Chemotherapy; Diagnosis; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic stem cells; Histone-Lysine N-Methyltransferase - genetics; Humans; KMT2A; Leukemia; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - mortality; Leukemia, Myeloid, Acute - therapy; Male; measurABLe residual disease; Medical prognosis; Middle Aged; MLL protein; multiparameter flow cytometry; Myeloid-Lymphoid Leukemia Protein - genetics; Prognosis; Recurrence; Risk factors; Stem cell transplantation; Transplantation, Homologous; Young Adult; measurABLe residual disease; multiparameter flow cytometry; KMT2A; acute myeloid leukaemia; allogeneic haematopoietic stem cell transplantation

Summary This study evaluated the kinetics of KMT2A‐r during chemotherapy and its impact on allogeneic haematopoietic stem cell transplantation (allo‐HSCT) outcomes. KMT2A‐r was assessed post‐induction (MRD1), after the first (MRD2) and second (MRD3) consolidations and pre‐transplant (MRD4) in 52 pat...